Business Context and Reporting Period
This Form 8-K filing by Novavax, Inc. (NVAX) reports on events occurring on May 8, 2019. The filing details the approval and implementation of a reverse stock split and the results of a Special Meeting of Stockholders held on that date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance actions and capital structure adjustments rather than operational financial performance.
Material Changes
- Reverse Stock Split: The Company filed a Certificate of Amendment to effect a 1-for-20 reverse stock split of its common stock. This action is effective at 12:01 a.m. Eastern Time on May 10, 2019.
- Trading Status: Post-split trading is expected to commence on May 10, 2019, under CUSIP number 670002 401.
- Share Count: As of the Record Date (March 25, 2019), there were 469,453,883 shares outstanding.
Guidance, Outlook, and Voting Results
The filing does not contain management guidance, outlook, or discussion of risks and contingencies. It reports the following voting results from the Special Meeting:
- Proposal 1 (Reverse Stock Split): Approved.
- Votes For: 242,781,304
- Votes Against: 97,608,654
- Abstaining: 4,627,457
- Broker Non-Votes: 124,436,468
Investor Verification Checklist
- Confirm the effective date and time of the 1-for-20 reverse stock split (May 10, 2019, 12:01 a.m. ET).
- Verify the new CUSIP number (670002 401) for post-split trading.
- Review the impact of the reverse split on the number of shares held and the adjusted share price.
- Check subsequent filings for any financial updates or liquidity status following this capital structure change.